Curemark | Welcome

Curemark

Autism

Dysautonomias

ADHD

Parkinsons Disease

Click on these pictures to learn more about Curemark's pipeline.

Breaking News

Curemark LLC Reports Positive Phase III Results of CM-AT In Children With Autism
12/07/2011
RYE, New York, Dec. 7, 2011 – Curemark LLC, a Rye, New York-based drug research...
Curemark Reports Positive Results for Novel Compound CM-182 in Amphetamine Induced Hyperactivity
08/29/2011
Curemark Reports Positive Results for Novel Compound CM-182 in Schizophrenia Mouse Model
04/25/2011

Curemark is a socially driven biotechnology and development company whose focus is addressing the unmet health needs of individuals in the areas of neurology and gastrointestinal/pancreatic secretory deficiencies.